Neil H. Bander

Also affiliated with Convergent Science (United States), Weill Cornell Medicine

MedicineChemistryImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 27 papers. Top paper: “Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591”.

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

The Prostate(2021)10.1002/pros.24104

N/A

1.5DataRank · unranked

27 citations

Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

JCI Insight(2023)10.1172/jci.insight.162907

N/A

0.663DataRank · unranked

82 citations

Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi +20 more

A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals

European Journal of Nuclear Medicine and Molecular Imaging(2021)10.1007/s00259-020-05150-w

N/A

0.584DataRank · unranked

48 citations

Sang Gyu Lee, Katerina Jou, Goutam Chakraborty, Myrto Skafida, Scott T. Tagawa +9 more

Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

The Oncologist(2020)10.1634/theoncologist.2020-0028

N/A

0.550DataRank · unranked

38 citations

Jaspreet S. Batra, Ryan D. Walsh, Marigdalia K. Ramirez‐Fort, Shankar Vallabhajosula, Yuliya Jhanwar +6 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5070

N/A

0.104DataRank · unranked

1 citations

Charlene Thomas, Gabriel Raab, Aaron N. Holmes, Tobechukwu Okobi, Andres Ricaurte‐Fajardo +11 more

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.05.028

N/A

0DataRank · unranked

49 citations

Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos +8 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17007

N/A

0DataRank · unranked

1 citations

Juana Martinez Zuloaga, Kritika Subramanian, Peter Gregos, Mahelia Bissassar, Sharon Singh +13 more

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5074

N/A

0DataRank · unranked

5 citations

Charlene Thomas, Jones T. Nauseef, Oliver Sartor, Michael Philip Sun, Sandra Huicochea Castellanos +14 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

The Prostate(2020)10.1002/pros.24056

N/A

0DataRank · unranked

28 citations

Kenneth J. Pienta, John W. Babich, Neil H. Bander, Jérémie Calais, Peter L. Choyke +11 more

Folate Hydrolase-1 (Folh1) is a Novel Target for Antibody-Based Brachytherapy in Merkel Cell Carcinoma

Skin Health and Disease(2020)10.1002/ski2.9

N/A

0DataRank · unranked

5 citations

Barbara Meier, Kristina Lachance, Sean S. Mahase, Candice D. Church, Muhammad Junaid Niaz +16 more

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.07.24.220277

N/A

0DataRank · unranked

13 citations

Sang Gyu Lee, Katerina Jou, Goutam Chakraborty, Myrto Skafida, Scott T. Tagawa +9 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

UNC Libraries(2020)10.17615/41rk-2070

N/A

0DataRank · unranked

0 citations

Matthew D. Galsky, Iain J. Webb, Jesika Petruck, Michael J. Morris, Robert Dreicer +7 more

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology(2021)10.3389/fonc.2021.630589

N/A

0DataRank · unranked

43 citations

Muhammad Junaid Niaz, Michael Sun, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

European Urology Focus(2021)10.1016/j.euf.2021.02.006

N/A

0DataRank · unranked

21 citations

Neil H. Bander, Scott T. Tagawa, Jones T. Nauseef